Syngene International Share Price Falling: Key Reasons, Analysis and 2026 Recovery Outlook
- May 5, 2026
- Posted by: Kashish Aggarwal
- Category: News
The Syngene International share price falling trend of 43 percent from its 52 week high of Rs 760 to the current price of Rs 432 has made it one of the most widely discussed stock corrections in the Contract Research and Development CDMO Pharma space in FY26. For a company with a market capitalisation of approximately Rs 15840 crore, this drawdown demands a structured explanation. This article examines every key reason behind the Syngene International share price falling, provides financial performance analysis based on publicly available data, assesses institutional positioning and offers a realistic view of recovery potential for 2026. Track the live Syngene International share price and fundamentals at the Univest Syngene International Stock Page.
Syngene International Current Price Position and 52 Week Range
Syngene International (NSE: SYNGENE) is a listed company in India’s Contract Research and Development CDMO Pharma sector with a market capitalisation of approximately Rs 15840 crore. The stock is trading at Rs 432 against a 52 week high of Rs 760 and a 52 week low of Rs 380, representing a correction of 43 percent from the annual peak. The Syngene International share price falling trend has placed the stock well below its 52 week high, and the wide gap from peak to current price has drawn the attention of both existing shareholders and prospective investors evaluating whether the current price represents risk or opportunity.
| Parameter | Value |
|---|---|
| NSE Ticker | SYNGENE |
| Sector | Contract Research and Development CDMO Pharma |
| Current Market Price (April 2026) | Rs 432 |
| 52 Week High | Rs 760 |
| 52 Week Low | Rs 380 |
| Market Capitalisation | Rs 15840 crore (approx) |
| Trailing P/E | 62x |
| Decline from 52 Week High | 43% |
Key Reasons Why Syngene International Share Price Is Falling in 2026
The Syngene International share price falling by 43 percent is not the result of a single event. It reflects a combination of company-specific earnings headwinds, sector-level pressures and a macro environment that has been deeply challenging for Indian equities since late 2024. The US 26 percent reciprocal tariff on Indian goods announced on April 2, 2026, triggered the most recent leg of the market correction, adding to the pre-existing downward pressure on Syngene International’s stock from the Rs 760 peak. Below is a structured analysis of each primary driver behind the Syngene International share price decline.
Why Is Syngene International Share Price Falling: Broad Market Correction and US Tariff Macro Shock
One of the primary reasons behind the Syngene International share price falling is the broad-based correction in Indian equities that began in late 2024 and has been sustained through April 2026. The Nifty 50 corrected over 14 percent from its all-time highs, and mid-cap and small-cap stocks like Syngene International faced disproportionate selling pressure as institutional investors repositioned portfolios. The US 26 percent reciprocal tariff announcement on April 2, 2026 added an acute macro shock that triggered a fresh wave of FII risk-off selling across Indian markets, affecting virtually every sector including the Contract Research and Development CDMO Pharma space where Syngene International operates. FII net selling in Indian equities has been substantial through FY26, with this institutional selling amplifying the company-specific earnings concerns and pushing Syngene International further below its Rs 760 peak.
Why Is Syngene International Share Price Falling: CRO and CDMO Demand Slowdown from Global Pharma
Syngene International operates in the Contract Research and Development Manufacturing space, where revenue is directly linked to the R&D and manufacturing outsourcing budgets of global pharmaceutical companies. In FY26, the global biotech funding correction and tightening R&D budgets at major pharma companies in the US and Europe have reduced outsourcing demand. Project ramp-up timelines have extended, deal closures have slowed, and capacity utilisation at Syngene International’s facilities has been below peak levels, directly contributing to the Syngene International share price falling by 43 percent from Rs 760 to Rs 432.
Why Is Syngene International Share Price Falling: Profit Decline from Exceptional and Operational Charges
Syngene International has reported a significant decline in quarterly profitability in FY26, driven by a combination of exceptional charges including employee severance costs, provisions for under-performing contracts, and infrastructure maintenance costs at its expanded research campus. These one-time and recurring charges have compressed the net profit margin well below the levels that supported the Rs 760 peak valuation. Investors tracking Syngene International have been disappointed by the profit shortfall, which is a primary trigger for the Syngene International share price falling trend.
Why Is Syngene International Share Price Falling: Leadership Transition Creating Execution Uncertainty
The announcement of a leadership transition at Syngene International, with the outgoing Managing Director and CEO stepping down and a successor being appointed, has created near-term execution uncertainty. Institutional investors typically apply a transition discount during periods of management change, particularly for specialised businesses where strategic continuity is critical. This uncertainty about the future strategic direction has been a contributing factor to the Syngene International share price falling from the Rs 760 peak as investors wait for clarity.
Why Is Syngene International Share Price Falling: Capacity Expansion Creating Depreciation and Cost Drag
Syngene International has been executing significant capital expenditure to expand its research and manufacturing campus capacity. This expansion creates depreciation charges, higher fixed operating costs and interest expenses before the capacity translates into incremental revenue. In a demand environment where client outsourcing decisions are being deferred, this cost drag relative to a slower revenue ramp has compressed margins below investor expectations and contributed to the Syngene International share price falling from Rs 760 to Rs 432.
Why Is Syngene International Share Price Falling: US Tariff Macro Uncertainty Affecting Global Pharma Clients
The US reciprocal tariff environment announced in April 2026 has created uncertainty in the global pharmaceutical sector, with US drug manufacturers reassessing supply chain strategies. While India has shown in negotiations that the pharma sector may receive preferential treatment, the uncertainty itself has delayed outsourcing decisions by Syngene International’s global pharmaceutical clients. This demand pause amplified the existing pressures and accelerated the Syngene International share price falling trend from the Rs 760 peak.
Syngene International Financial Performance and Valuation Context
The table below provides a high-level financial context for understanding the gap between the Syngene International share price at its Rs 760 peak and the current level of Rs 432. All revenue and profit data should be verified from NSE or BSE exchange filings as the authoritative source.
| Metric | FY24 | FY25 | FY26 Estimate |
|---|---|---|---|
| Revenue (Rs Cr) | Refer to NSE filing | Refer to NSE filing | Refer to NSE filing |
| Net Profit (Rs Cr) | Refer to NSE filing | Refer to NSE filing | Refer to NSE filing |
| Market Cap (approx) | Rs 15840 crore | Higher at Rs 760 peak | Compressed with price |
| Trailing P/E | 62x | Higher at Rs 760 peak | De-rated at Rs 432 |
| 52 Week Range | Rs 380 to Rs 760 | ||
Technical Analysis of Syngene International Stock in April 2026
Syngene International is trading at Rs 432, well below its 50 day, 100 day and 200 day simple moving averages, confirming a strong downtrend. The stock has been making lower highs and lower lows consistently since the Rs 760 52 week peak, a bearish technical pattern. Key support is at the 52 week low of Rs 380, and a sustained breach below this level could trigger further selling. For recovery to be technically confirmed, Syngene International would need to reclaim the intermediate resistance zone meaningfully above the current price. Download the Univest Android App for live price alerts and SEBI-registered analyst research on Syngene International.
Can Syngene International Share Price Recover in 2026
Despite the headwinds, genuine recovery catalysts exist for Syngene International. Any quarterly earnings result that beats the now-reduced analyst consensus would be a positive trigger. A macro normalisation, particularly if the US-India tariff situation de-escalates through trade negotiations, would improve the FII sentiment toward Indian equities broadly, benefiting Syngene International alongside the market. Sector-specific positive developments such as demand recovery, input cost deflation or favourable policy changes could provide company-specific catalysts. At Rs 432, which is 43 percent below the Rs 760 peak, the downside risks are more reflected in the price than at the 52 week high. Patient investors with a 24 to 36 month horizon should monitor the next 2-3 quarterly results and any shift in FII ownership trends.
Conclusion
The Syngene International share price falling by 43 percent from its 52 week high of Rs 760 to Rs 432 reflects a combination of company-specific challenges, sector-wide headwinds, FII selling pressure and macro factors including the US tariff shock of April 2026. Investors should monitor quarterly results, FII ownership trends and management commentary before making investment decisions on Syngene International stock.
This article is for informational purposes only. Please conduct your own research and consult a SEBI registered financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. Please read all related documents carefully before investing.
Frequently Asked Questions
Why is Syngene International share price falling in 2026?
The Syngene International share price falling in 2026 is driven by sector-specific headwinds in Contract Research and Development CDMO Pharma, FII selling across Indian equities, broad market correction from late 2024 and the US tariff macro shock of April 2026. Company-specific earnings deceleration and valuation de-rating from the Rs 760 peak have amplified the decline to Rs 432.
What is the 52 week high and low of Syngene International?
The 52 week high of Syngene International (NSE: SYNGENE) is Rs 760 and the 52 week low is Rs 380. The current price of Rs 432 represents a decline of 43 percent from the 52 week high, placing the stock in the lower portion of its annual trading range. This 43 percent gap from the annual peak is central to the Syngene International share price falling story in FY26.
Is Syngene International a good buy at current price?
Whether Syngene International at Rs 432 is a good buy depends on your investment horizon, risk appetite and conviction in the earnings recovery thesis. The stock has declined 43 percent from its 52 week high, which improves the risk-reward for investors with a 2 to 3 year view if earnings stabilise and recover. However, near-term volatility may persist given the ongoing sector headwinds. Consult a SEBI registered financial advisor before any investment decision. The Syngene International share price falling trend could continue if earnings continue to disappoint.
What is the current market cap of Syngene International?
Syngene International has a market capitalisation of approximately Rs 15840 crore at the current price of Rs 432. This represents a significant compression from the market cap implied at the 52 week high of Rs 760, reflecting the value destruction during the Syngene International share price falling phase. Track live market cap and fundamentals at the Univest Syngene International Stock Page.
What are the recovery triggers for Syngene International?
Key recovery triggers for Syngene International include a quarterly earnings result that beats reduced analyst expectations, reversal of FII selling as global macro conditions normalise, positive sector developments in Contract Research and Development CDMO Pharma, and broader recovery of Indian equities from the April 2026 tariff correction. Any of these catalysts could initiate a meaningful rebound from the current Rs 432 and reverse the Syngene International share price falling trend.
What is the target price of Syngene International for 2026?
Analyst consensus 12-month target prices for Syngene International vary across brokerages. Investors should track live analyst ratings and target prices through the Univest screener or SEBI-registered research platforms. The Syngene International share price falling from Rs 760 to Rs 432 implies that even a reversion to the midpoint of the 52 week range would represent significant upside from the current price. However, any target is contingent on earnings recovery materialising as analysts currently project.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
